8-K - Annovis Bio, Inc. (0001477845) (Filer)
Published . Updated .
Key takeaways
- 8-K - Annovis Bio filed an 8-K with the SEC on Oct 30 (a notice of a material company event).
- Exposed: ANVS
- Market reaction: ANVS −41.5% after three sessions
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K - Annovis Bio filed an 8-K with the SEC on Oct 30 (a notice of a material company event).
Directly affected
- ANVS Annovis Bio-9.4% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Annovis Bio belongs to, so it often moves with news about it.
- LLY Eli Lilly and+19.9% 30d
Eli Lilly and is a peer of Annovis Bio in pharmaceutical preparations; rivals often move on the same news.
- JNJ Johnson & Johnson+1.9% 30d
Johnson & Johnson is a peer of Annovis Bio in pharmaceutical preparations; rivals often move on the same news.
- ABBV AbbVie+11.3% 30d
AbbVie is a peer of Annovis Bio in pharmaceutical preparations; rivals often move on the same news.
- MRK Merck+5.9% 19d
Merck is a peer of Annovis Bio in pharmaceutical preparations; rivals often move on the same news.
- ABT Abbott Laboratories+12.7% 30d
Abbott Laboratories is a peer of Annovis Bio in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| ANVS | -15.92% | -9.73% | base | -3.54% | -1.77% | +6.19% | -41.47% |
| XLV | -3.03% | -2.77% | base | -0.14% | -0.48% | +2.59% | +0.17% |
| LLY | -9.71% | -8.92% | base | -0.37% | -0.54% | +0.07% | -3.00% |
| JNJ | -2.53% | -0.72% | base | -0.98% | -2.59% | +1.13% | -0.32% |
| ABBV | -2.71% | -2.90% | base | -2.03% | -3.03% | -0.45% | -1.91% |
| MRK | -5.94% | -5.65% | base | -0.74% | -3.26% | +0.55% | -1.48% |
| ABT | -1.26% | -3.36% | base | +3.81% | +2.97% | +9.08% | +6.88% |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-10-30 AccNo: 0001104659-26-120732 Size: 215 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements a…
Source: sec-edgar
The price since 30 Oct 2026: Annovis Bio (ANVS) versus the S&P 500
Since the first closing price after “8-K - Annovis Bio, Inc. (0001477845) (Filer),” Annovis Bio (ANVS) is +10.09%.
| Company | When | Move | Status |
|---|---|---|---|
| ABBV | that day | -2.03% | final price |
| ABBV | the next day | -3.03% | final price |
| ABBV | two days later | -0.45% | final price |
| ABBV | three days later | -1.91% | final price |
| ABBV | three days earlier | -2.90% | final price |
| ABBV | five days earlier | -2.71% | final price |
| ABT | that day | +3.81% | final price |
| ABT | the next day | +2.97% | final price |
| ABT | two days later | +9.08% | final price |
| ABT | three days later | +6.88% | final price |
| ABT | three days earlier | -3.36% | final price |
| ABT | five days earlier | -1.26% | final price |
| Annovis Bio (ANVS) | that day | -3.54% | final price |
| Annovis Bio (ANVS) | the next day | -1.77% | final price |
| Annovis Bio (ANVS) | two days later | +6.19% | final price |
| Annovis Bio (ANVS) | three days later | -41.47% | final price |
| Annovis Bio (ANVS) | three days earlier | -9.73% | final price |
| Annovis Bio (ANVS) | five days earlier | -15.92% | final price |
| JNJ | that day | -0.98% | final price |
| JNJ | the next day | -2.59% | final price |
| JNJ | two days later | +1.13% | final price |
| JNJ | three days later | -0.32% | final price |
| JNJ | three days earlier | -0.72% | final price |
| JNJ | five days earlier | -2.53% | final price |
| LLY | that day | -0.37% | final price |
| LLY | the next day | -0.54% | final price |
| LLY | two days later | +0.07% | final price |
| LLY | three days later | -3.00% | final price |
| LLY | three days earlier | -8.92% | final price |
| LLY | five days earlier | -9.71% | final price |
| MRK | that day | -0.74% | final price |
| MRK | the next day | -3.26% | final price |
| MRK | two days later | +0.55% | final price |
| MRK | three days later | -1.48% | final price |
| MRK | three days earlier | -5.65% | final price |
| MRK | five days earlier | -5.94% | final price |
| XLV | that day | -0.14% | final price |
| XLV | the next day | -0.48% | final price |
| XLV | two days later | +2.59% | final price |
| XLV | three days later | +0.17% | final price |
| XLV | three days earlier | -2.77% | final price |
| XLV | five days earlier | -3.03% | final price |
Congressional trades in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 56 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 30 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 35 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 52 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Pete Sessions sold AbbVie (ABBV), worth $15,001 - $50,000 on 14 Sep 2026. That is 46 days before publication. Filed 18 Sep 2026. View the filing.
- Rep. Rohit Khanna sold AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 56 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 36 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 72 days before publication. Filed 9 Sep 2026. View the filing.
- Rep. Pete Sessions sold Abbott Laboratories (ABT) (held by a spouse), worth $50,001 - $100,000 on 2 Oct 2026. That is 28 days before publication. Filed 27 Oct 2026. View the filing.
- Rep. Gilbert Cisneros bought Abbott Laboratories (ABT), worth $1,001 - $15,000 on 18 Sep 2026. That is 42 days before publication. Filed 12 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Abbott Laboratories (ABT), worth $1,001 - $15,000 on 17 Sep 2026. That is 43 days before publication. Filed 30 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who is named in “8-K - Annovis Bio, Inc. (0001477845) (Filer)”
Companies tied to this story
- ANVS Annovis Bio
In “8-K - Annovis Bio, Inc. (0001477845) (Filer),” Annovis Bio (ANVS) is linked, with no stored direction, high confidence. Reason on file: SEC 8-K filing -> direct issuer disclosure -> ANVS
How “8-K - Annovis Bio, Inc. (0001477845) (Filer)” reaches Annovis Bio (ANVS)
On 30 Oct 2026, “8-K - Annovis Bio, Inc. (0001477845) (Filer)” is the story that connects Annovis Bio (ANVS) to this story.
Annovis Bio (ANVS) is on the page because SEC 8-K filing -> direct issuer disclosure -> ANVS
Price levels for Annovis Bio (ANVS)
ANVS traded between 0.94 and 1.39 across 20 sessions. The latest close on file is 1.20.
How solid “8-K - Annovis Bio, Inc. (0001477845) (Filer)” looks
14 out of 100
“8-K - Annovis Bio, Inc. (0001477845) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.